quinoxalines has been researched along with Schizophrenia in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.53) | 18.2507 |
| 2000's | 5 (13.16) | 29.6817 |
| 2010's | 27 (71.05) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Humair, JP; Papachristou, C | 1 |
| George, TP; Kozak, K | 1 |
| Hu, K; Kocsis, B; Pittman-Polletta, B | 1 |
| Abdul-Malak, Y; Ajagbe, TO; Batki, SL; Dimmock, JA; Meszaros, ZS; Wang, D | 1 |
| Porwal, M; Tsoi, DT; Webster, AC | 1 |
| Fatemi, SH; Folsom, TD; Kneeland, RE; Liesch, SB; Thuras, PD; Yousefi, MK | 1 |
| Bacher, I; George, TP; Rabin, RA; Wass, CE; Wing, VC | 1 |
| Evins, AE; Fullerton, CA; Hoeppner, SS; Roh, S; Schoenfeld, D; Stoeckel, LE | 1 |
| Achtyes, ED; Ayer, D; Cather, C; Evins, AE; Goff, DC; Hoeppner, SS; Pachas, GN; Pratt, SA; Schoenfeld, DA | 1 |
| Bundo, M; Iwamoto, K; Kato, T; Kubota-Sakashita, M | 1 |
| Beard, JD; Davis, RE; Hendrick, JP; Lee, T; Li, P; Mates, S; Peng, Y; Robichaud, AJ; Snyder, GL; Tomesch, J; Vanover, KE; Wennogle, LP; Yao, W; Zhang, Q; Zhu, H | 1 |
| Adell, A; Auberson, YP; Campa, L; Jiménez-Sánchez, L | 1 |
| Freedman, R; Indersmitten, T; Leonard, S; Lester, HA; Wang, Y; Xiao, C | 1 |
| Becker, C; Bencherif, M; Kucinski, A; Lippiello, P; Stachowiak, EK; Stachowiak, MK; Wersinger, S | 1 |
| Devadoss, T; Mahesh, R; Modak, N; Pandey, DK | 1 |
| Fatemi, SH | 1 |
| Evins, AE; Goff, DC | 1 |
| Cornwell, J; Davis, JM; Gupta, S; Lajtha, A; Lindenmayer, JP; Noth, K; Sershen, H; Smith, RC | 1 |
| Anghelescu, I | 1 |
| Adler, LE; Waldo, MC; Woodward, L | 1 |
| Blumberger, D; George, TP; Ismail, Z; Syms, J | 1 |
| Costa, E; Davis, JM; Guidotti, A; Lajtha, A; Maloku, E; Sershen, H; Smith, RC; Zhubi, A | 1 |
| Tavares, AR; Volpe, FM | 1 |
| Buchanan, RW; Buchholz, A; Coffay, A; Kelly, DL; Liu, F; McMahon, RP; Weiner, E | 1 |
| Chen, MC; Jeang, SY; Liu, ME; Peng, SL; Tsai, SJ; Tsai, YL; Wu, SL; Yang, ST | 1 |
| Carlini, SV; Dutra, SJ; Evins, AE; Pizzagalli, DA; Stoeckel, LE | 1 |
| Buchanan, RW; Fuller, RL; Heishman, SJ; Hong, LE; McMahon, RP; Myers, C; Nye, A; Rachbeisel, J; Summerfelt, A; Thaker, GK; Wonodi, I; Yang, J | 1 |
| Cho, DM; Jung, DU; Jung, SS; Kang, JW; Kelly, DL; Kim, SD; Kong, BG; Lee, JH; Lee, SW; McMahon, RP; Oh, MK; Seo, YS; Shim, JC | 1 |
| Hrupka, B; Pemberton, DJ; Pollard, M; Shaban, H; Steckler, T; Varin, C | 1 |
| Adams, M; Bastiampillai, T; Gupta, A; Nance, M; Nelson, A | 1 |
| Anthenelli, RM; George, TP; Morris, CD; Thompson, JR; Treadow, J; Williams, JM; Yunis, C | 1 |
| Cerimele, JM; Durango, A | 1 |
| Baker, AL; Castle, D; Filia, SL; Harris, D; Pirola-Merlo, AJ; Richmond, R | 1 |
| Freedman, R | 1 |
| Healy, DJ; Meador-Woodruff, JH | 1 |
| Conca, A; König, P; Lugmayer, B | 1 |
| Barturen, F; García-Sevilla, JA; Meana, JJ | 1 |
| Kerwin, R; Meldrum, B; Patel, S | 1 |
3 review(s) available for quinoxalines and Schizophrenia
| Article | Year |
|---|---|
Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.
Topics: Benzazepines; Bupropion; Humans; Nicotinic Agonists; Quinoxalines; Schizophrenia; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2020 |
Interventions for smoking cessation and reduction in individuals with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Reinforcement, Psychology; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Varenicline | 2013 |
Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies.
Topics: Adverse Drug Reaction Reporting Systems; Attention; Benzazepines; Cognition Disorders; Disease Progression; Dose-Response Relationship, Drug; Humans; Nicotinic Agonists; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Quinoxalines; Risk Factors; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Treatment Outcome; Varenicline | 2012 |
12 trial(s) available for quinoxalines and Schizophrenia
| Article | Year |
|---|---|
Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Benzazepines; Diagnosis, Dual (Psychiatry); Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nicotinic Agonists; Pilot Projects; Quinoxalines; Schizophrenia; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2013 |
Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzazepines; Bupropion; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Nicotinic Agonists; Psychiatric Status Rating Scales; Psychotic Disorders; Quinoxalines; Schizophrenia; Smoking; Varenicline | 2013 |
Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Benzazepines; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Mecamylamine; Middle Aged; Neuropsychological Tests; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Reaction Time; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Task Performance and Analysis; Varenicline | 2014 |
Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.
Topics: Adult; Aged; Benzazepines; Bipolar Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Schizophrenia; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult | 2014 |
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzazepines; Carbon Dioxide; Cognition; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Neuropsychological Tests; Nicotine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinoxalines; Schizophrenia; Schizophrenic Psychology; Smoking; Time Factors; Varenicline | 2009 |
Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.
Topics: Acoustic Stimulation; Analysis of Variance; Benzazepines; Double-Blind Method; Evoked Potentials, Auditory; Humans; Nicotinic Agonists; Pilot Projects; Quinoxalines; Reaction Time; Schizophrenia; Sensory Gating; Statistics, Nonparametric; Varenicline | 2010 |
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.
Topics: Adult; Benzazepines; Double-Blind Method; Female; Humans; Male; Nicotinic Agonists; Pilot Projects; Quinoxalines; Schizophrenia; Smoking Cessation; Treatment Outcome; Varenicline | 2011 |
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.
Topics: Adult; Attention; Benzazepines; Biomarkers; Cognition; Double-Blind Method; Eye Movements; Female; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Nicotinic Agonists; Psychotic Disorders; Quinoxalines; Reflex, Startle; Schizophrenia; Schizophrenic Psychology; Sensory Gating; Smoking; Varenicline | 2011 |
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Benzazepines; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Nicotinic Agonists; Quinoxalines; Schizophrenia; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2012 |
A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Benzazepines; Canada; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Psychotic Disorders; Quinoxalines; Schizophrenia; Smoking Cessation; United States; Varenicline | 2012 |
Varenicline plus healthy lifestyle intervention for smoking cessation in psychotic disorders.
Topics: Adult; Benzazepines; Bipolar Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Life Style; Nicotinic Agonists; Psychotic Disorders; Quinoxalines; Schizophrenia; Severity of Illness Index; Smoking; Smoking Cessation; Varenicline | 2012 |
Does a glutamate receptor blocker (Caroverine) enhance haloperidol in the treatment of schizophrenia?
Topics: Adult; Antipsychotic Agents; Drug Synergism; Excitatory Amino Acid Antagonists; Female; Haloperidol; Humans; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Quinoxalines; Retrospective Studies; Schizophrenia; Schizophrenic Psychology | 1999 |
23 other study(ies) available for quinoxalines and Schizophrenia
| Article | Year |
|---|---|
[Tobacco cessation treatment for people with schizophrenia].
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Schizophrenia; Smoking Cessation; Tobacco Use Cessation; Tobacco Use Cessation Devices; Varenicline | 2022 |
Subunit-specific NMDAR antagonism dissociates schizophrenia subtype-relevant oscillopathies associated with frontal hypofunction and hippocampal hyperfunction.
Topics: Animals; Frontal Lobe; Hippocampus; Quinoxalines; Rats; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Theta Rhythm | 2018 |
Varenicline modulates spatial working memory deficits in smokers with schizophrenia.
Topics: Analysis of Variance; Benzazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Memory Disorders; Neuropsychological Tests; Nicotinic Agonists; Psychiatric Status Rating Scales; Quinoxalines; Schizophrenia; Schizophrenic Psychology; Smoking; Varenicline | 2013 |
A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia.
Topics: Adenosine Deaminase; Animals; Behavior, Animal; Brain; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mood Disorders; Motor Activity; Postmortem Changes; Quinoxalines; Receptors, AMPA; Receptors, Glutamate; RNA Editing; RNA-Binding Proteins; Schizophrenia | 2014 |
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biological Availability; Drug Discovery; Electroshock; Indicators and Reagents; Male; Mental Disorders; Nervous System Diseases; Quinoxalines; Quipazine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recombinant Proteins; Schizophrenia; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2014 |
The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Phenols; Piperidines; Prefrontal Cortex; Quinoxalines; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Serotonin; Stereotyped Behavior | 2014 |
The duplicated α7 subunits assemble and form functional nicotinic receptors with the full-length α7.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzazepines; Cell Line, Tumor; Choline; Gene Duplication; Humans; Membrane Potentials; Mice; Nicotinic Agonists; Protein Multimerization; Protein Structure, Quaternary; Protein Subunits; Protein Transport; Quinoxalines; Rats; Schizophrenia; Sequence Deletion; Varenicline | 2014 |
The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists.
Topics: Animals; Benzazepines; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Nicotinic Agonists; Quinoxalines; Receptors, Serotonin, 5-HT3; Reflex, Startle; Schizophrenia; Sensory Gating; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Varenicline | 2015 |
Antidepressant & anxiolytic activities of N-(pyridin-3-yl) quinoxalin-2-carboxamide: A novel serotonin type 3 receptor antagonist in behavioural animal models.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Depressive Disorder; Disease Models, Animal; Feeding and Eating Disorders; Male; Mice; Motor Activity; Obsessive-Compulsive Disorder; Quinoxalines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia; Serotonin; Serotonin 5-HT3 Receptor Antagonists | 2016 |
Varenicline efficacy and tolerability in a subject with schizophrenia.
Topics: Adult; Benzazepines; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Nicotinic Agonists; Quinoxalines; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Varenicline | 2008 |
Varenicline treatment for smokers with schizophrenia: a case series.
Topics: Benzazepines; Cholinergic Agonists; Drug Administration Schedule; Humans; Quinoxalines; Schizophrenia; Smoking; Smoking Cessation; Smoking Prevention; Varenicline | 2008 |
Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient.
Topics: Adult; Antipsychotic Agents; Benzazepines; Humans; Male; Psychiatric Status Rating Scales; Quinoxalines; Schizophrenia; Smoking; Smoking Cessation; Varenicline | 2009 |
Varenicline induced polydipsia and hyponatremia in a patient with schizophrenia.
Topics: Antipsychotic Agents; Benzazepines; Drinking; Drug Therapy, Combination; Humans; Hyponatremia; Male; Middle Aged; Nicotinic Agonists; Psychoses, Substance-Induced; Quinoxalines; Schizophrenia; Smoking Cessation; Varenicline; Water Intoxication | 2010 |
Varenicline treatment decreases DNMT1 mRNA expression in lymphocytes of schizophrenic patients who are cigarette smokers.
Topics: Benzazepines; Cotinine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; RNA, Messenger; Schizophrenia; Smoking Cessation; Varenicline | 2010 |
Electroconvulsive therapy (ECT) effective for psychotic recrudescence and suicidality after varenicline adjunctive therapy for smoking cessation in a schizoaffective patient.
Topics: Benzazepines; Electroconvulsive Therapy; Female; Humans; Middle Aged; Nicotinic Agonists; Quinoxalines; Schizophrenia; Smoking Cessation; Suicidal Ideation; Varenicline | 2010 |
Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia.
Topics: Adult; Analysis of Variance; Benzazepines; Cognition; Humans; Male; Middle Aged; Mood Disorders; Neuropsychological Tests; Nicotinic Agonists; Psychiatric Status Rating Scales; Quinoxalines; Regression Analysis; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Cessation; Time Factors; Treatment Outcome; Varenicline | 2011 |
Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.
Topics: Adult; Benzazepines; Cognitive Behavioral Therapy; Female; Humans; Male; Middle Aged; Psychomotor Performance; Quinoxalines; Reward; Schizophrenia; Smoking; Smoking Cessation; Varenicline | 2012 |
Synaptic transmission changes in fear memory circuits underlie key features of an animal model of schizophrenia.
Topics: Action Potentials; Amygdala; Animals; Area Under Curve; Biophysics; Disease Models, Animal; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Extinction, Psychological; Fear; Glutamate Decarboxylase; Hippocampus; In Vitro Techniques; Male; Memory Disorders; Neurons; Parvalbumins; Patch-Clamp Techniques; Phencyclidine; Quinoxalines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Schizophrenia; Synaptic Transmission; Time Factors | 2012 |
Varenicline induced psychosis in schizophrenia.
Topics: Adult; Benzazepines; Female; Humans; Nicotinic Antagonists; Psychoses, Substance-Induced; Quinoxalines; Schizophrenia; Tobacco Use Cessation Devices; Varenicline | 2012 |
Exacerbation of schizophrenia by varenicline.
Topics: Acute Disease; Benzazepines; Cognition Disorders; Comorbidity; Female; Humans; Middle Aged; Nicotine; Quinoxalines; Recurrence; Schizophrenia; Schizophrenic Psychology; Self Medication; Smoking; Smoking Cessation; Varenicline | 2007 |
Ionotropic glutamate receptor modulation of 5-HT6 and 5-HT7 mRNA expression in rat brain.
Topics: Animals; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Hippocampus; Male; Nootropic Agents; Pyrrolidinones; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, Serotonin; RNA, Messenger; Schizophrenia | 1999 |
Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Binding, Competitive; Brain; Brain Mapping; Brimonidine Tartrate; Clonidine; Depressive Disorder; Female; Humans; Male; Middle Aged; Quinoxalines; Radioligand Assay; Receptors, Adrenergic; Schizophrenia; Schizophrenic Psychology; Suicide; Violence | 1992 |
Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Adult; Aged; Autoradiography; Female; Glutamates; Hippocampus; Humans; Kainic Acid; Male; Middle Aged; N-Methylaspartate; Pyramidal Tracts; Quinoxalines; Receptors, Glutamate; Receptors, Neurotransmitter; Reference Values; Schizophrenia; Tritium | 1990 |